Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Acute lymphoblastic leukaemia|
|Citation:||Lancet, 2013; 381(9881):1943-1955|
|Hiroto Inaba, Mel Greaves, Charles G Mullighan|
|Abstract:||Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.|
|Keywords:||Central Nervous System Diseases|
|Rights:||© 2013 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||Genetics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.